TumCI Cancer Research Results

TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
1238- PTS,    Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention
- in-vitro, GC, NA - in-vivo, NA, NA
TumCCA↑, TumCP↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, Weight∅, JAK2↓, STAT3↓,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
4689- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
- in-vitro, Cerv, HeLa
eff↑, TumCCA↑, ROS↑, MMP2↓, MMP9↓, CSCs↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, BioAv↑, TumCI↓, ROS↑, Apoptosis↑,
3929- PTS,    New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects
- Review, Var, NA - Review, Arthritis, NA
*NRF2↑, *BioAv↑, *ROS↓, *Inflam↓, *HO-1↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *hepatoP↑, *neuroP↑, *iNOS↓, *COX2/PTGS2↓, TumMeta↓, SOD2↓, ROS↑, TumCI↓, TumCG↓, HDAC1↓, PTEN↑, BP↓, *GutMicro↑,
8381- QC,  LT,    Mechanism of Quercetin and Luteolin on Colon Cancer Metastasis: Network Pharmacological Study and Experimental Validation
- vitro+vivo, Colon, CT26
AntiCan↑, TumCG↓, TumCA↓, TumCMig↓, TumCI↓,
2340- QC,    Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)
- in-vitro, OS, NA
TumCG↓, GlucoseCon↓, TumCI↓, GLUT1↓, PKM2↓, LDHA↓, Glycolysis↓, lactateProd↓, HK2↓, eff↑,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
3375- QC,    Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells
- in-vitro, Melanoma, B16-BL6
TET1↑, TumCI↓,
3374- QC,    Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis
- Review, Oral, NA - Review, AD, NA
α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp/ABCB1↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP/DDIT3↑,
3373- QC,    The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway
- in-vitro, Pca, DU145
TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,
56- QC,    Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells
- in-vitro, PC, PANC1 - in-vitro, PC, PATU-8988
EMT↓, MMPs↓, MMP2↓, MMP7↓, STAT3↓, TumCI↓, TumMeta↓, tumCV↓,
57- QC,    Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo
- vitro+vivo, PC, PC3
TSP-1↑, angioG↓, TumCMig↓, TumCI↓,
59- QC,    Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM)
- in-vitro, BC, MDA-MB-231
ALDH1A1↓, CXCR4↓, MUC1↓, EpCAM↓, CSCs↓, TumCP↓, TumCI↓, CD44↓, CD24↓, Apoptosis↑, TumCCA↑,
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,
96- QC,  docx,    Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp/ABCB1↓, TumCP↓, TumCMig↓, TumCI↓,
90- QC,  HYP,    Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21
- in-vitro, Pca, PC3
ROS↑, cl‑Casp3↑, cl‑PARP↑, miR-21↓, PDCD4↑, TAC↑, tumCV↓, TumCI↓,
85- QC,    Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)
- in-vitro, Pca, PC3
uPA↓, uPAR↓, EGFR↓, NRAS↓, Jun↓, NF-kB↓, β-catenin/ZEB1↓, p38↑, MAPK↑, cJun↓, cFos↓, Raf↓, TumCI↓, TumCMig↓,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2/PTGS2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1/ATG6↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, Synergy↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
3095- RES,    Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk
- in-vitro, BC, NA
TumCP↓, TumCMig↓, TumCI↓, cycD1/CCND1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
101- RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑, TumCI↓, TumMeta↓,
877- RES,    Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway
- in-vitro, CRC, LoVo - in-vitro, CRC, HCT116
MALAT1↓, Wnt/(β-catenin)↓, TumCI↓, TumMeta↓,
7150- RES,    Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity
- Review, Var, NA
AntiTum↑, PI3K↓, Akt↓, *AntiAge↑, *SIRT1↑, *lipid-P↓, *ROS↓, *BioAv↓, *NRF2↑, *HO-1↑, SOD↑, HDAC1↓, PTEN↑, P53↑, TumCCA↑, TumCI↓, TumMeta↓, EMT↓, MMPs↓, MMP9↓, angioG↓, VEGF↓, EGFR↓, FGF21↓, HIF-1↓, *neuroP↑, *cardioP↑, BMPs↑, ROS↑, Vim↓, N-cadherin↓, MMP3↓, MMP13↓, E-cadherin↑, Ki-67↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3035- RosA,    Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- in-vitro, PC, NA - in-vivo, NA, NA
Gli1↓, TumCCA↑, TumCMig↓, TumCI↓, CDK2↓, cycE/CCNE↓, P21↑, p27/CDKN1B↑,
1048- RosA,  GSL,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2/PTGS2↓, PD-L1↓,
7378- RS,    Reserpine inhibits DNA repair, cell proliferation, invasion and induces apoptosis in oral carcinogenesis via modulation of TGF-β signaling
- in-vitro, Oral, NA
*antiOx↑, *AntiBio↑, TGF-β↓, p‑SMAD3↓, p‑SMAD2↓, p‑SMAD4↓, SMAD3↓, Snail↓, ERCC1↓, ERCC4/XPF↓, Ku70/XRCC6↓, PCNA↓, cycD1/CCND1↓, Hif1a↓, IL6↓, Mcl-1↓, BAX↑, Cyt‑c↑, APAF1↑, Casp9↑, Casp3↑, PARP↑, DNArepair↓, TumCP↓, TumCI↓,
5127- Sal,    Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway
- in-vitro, Ovarian, NA
TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Wnt↓, β-catenin/ZEB1↓, TumCP↓, TumCMig↓, EMT↓,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27/CDKN1B↑, CHOP/DDIT3↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
5042- SAS,    xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
- Review, Var, NA
xCT/SLC7A11↓, GSH↓, TumCG↓, TumCI↓, ROS↑, RadioS↑, eff↓,
5035- SAS,    Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use
- Human, GC, NA - in-vitro, GC, NCI-N87 - in-vitro, GC, SGC-7901
other?, TumCP↓, TumMeta↓, TumCI↓, xCT/SLC7A11↓, OS↑,
3188- SFN,    Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells
- in-vitro, BC, NA
TNF-α↓, TumCI↓, TumMeta↓, MMPs↓, MMP2↓, MMP9↓, MMP13↓,
111- SFN,    Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling
- in-vitro, BC, SUM159
HH↓, Gli1↓, MMP2↓, MMP9↓, Smo↓, TumCMig↓, TumCI↓,
2166- SFN,    Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction
- in-vitro, Oral, NA - in-vivo, NA, NA
CSCs↓, selectivity↑, TumCMig↓, TumCI↓,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2/PTGS2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2/PTGS2↝, MMP2↝, MMP9↝,
1457- SFN,    Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
- in-vitro, CRC, HT-29
IL6↓, ROS↓, TumCP↓, TumCI↓, p38↓, AP-1↓,
1452- SFN,    Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells
- in-vitro, GC, AGS
MMP9↓, p38↓, ERK↓, AP-1↓, ROS↓, NF-kB↓, TumCI↓, MMP9↓, HDAC↓, Glycolysis↓, Hif1a↓, *memory↑, *cognitive↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2/KDR/Flk1↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,

Showing Research Papers: 451 to 500 of 548
Prev Page 10 of 11 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 548

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,   NA?, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↑, 1,   antiOx↓, 2,   antiOx↑, 6,   ARE↓, 1,   Catalase↓, 3,   Copper↑, 1,   ENOX2↓, 1,   Fenton↑, 2,   GPx↓, 1,   GPx↑, 2,   GPx1↓, 1,   GPx4↓, 13,   GSH↓, 27,   GSH↑, 2,   GSR↓, 1,   GSTs↑, 1,   H2O2↓, 2,   H2O2↑, 2,   HO-1↓, 5,   HO-1↑, 9,   Iron↑, 4,   i-Iron↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P?, 1,   lipid-P↓, 3,   lipid-P↑, 8,   MDA?, 1,   MDA↑, 7,   i-MDA↑, 1,   NADH↓, 2,   NQO1?, 1,   NQO1↑, 1,   NRF2↓, 16,   NRF2↑, 15,   Prx↓, 1,   Prx4↑, 1,   PrxII↓, 1,   PYCR1↓, 1,   ROS↓, 19,   ROS↑, 147,   ROS⇅, 2,   ROS↝, 2,   ROS∅, 1,   i-ROS↓, 1,   i-ROS↑, 1,   mt-ROS↑, 5,   SOD↓, 5,   SOD↑, 2,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 4,   SOD2↑, 1,   TAC↓, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 2,   ox-Trx1↑, 1,   TrxR↓, 5,   TrxR1↓, 3,   xCT/SLC7A11↓, 5,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh∅, 1,   Tf↓, 1,   Tf↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   CDC2↓, 4,   CDC25↓, 6,   compI↓, 1,   compIII↓, 1,   compV↓, 1,   compV↓, 1,   EGF↓, 1,   ETC↓, 3,   MFN2↓, 1,   mitResp↑, 1,   Mortalin↓, 1,   mtDam↑, 14,   OCR↓, 6,   OCR↑, 1,   OXPHOS↓, 2,   OXPHOS↑, 5,   mt-OXPHOS↓, 1,   PDH↑, 2,   PDH↝, 1,   PDH∅, 1,   PGC-1α↑, 1,   PINK1↑, 3,   SIRT3↑, 2,   VDAC1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 2,   5LO↓, 3,   ACADS/SCAD↓, 1,   ACC↓, 2,   ACLY↓, 1,   ACSL4↑, 1,   ALAT↓, 2,   AMPK↓, 1,   AMPK↑, 25,   AMPK↝, 1,   p‑AMPK↑, 5,   ATP↓, 19,   CAIX/CA9↓, 1,   citrate↓, 1,   ECAR↓, 3,   ENO1↓, 1,   FABP4↑, 1,   FABP5/E-FABP↓, 1,   FAM↓, 1,   FASN↓, 6,   FDG↓, 1,   G6PD↓, 5,   GAPDH↓, 2,   GLS↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 11,   GlutMet↓, 1,   Glycolysis↓, 34,   GSK‐3β↓, 10,   GSK‐3β↑, 1,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 1,   Histones↑, 1,   ac‑Histones↑, 1,   HK1↓, 1,   HK2↓, 17,   HMG-CoA↓, 1,   IDH1↑, 1,   lactateProd↓, 11,   lactateProd↑, 1,   LDHA↓, 11,   LDHA∅, 1,   LDL↓, 3,   lipidLev↓, 2,   lipoGen↓, 2,   NADPH↓, 1,   PDHB↓, 1,   PDK1 / PDPK1↓, 5,   p‑PDK1 / PDPK1↓, 1,   PFK↓, 4,   PFK1↓, 1,   PGK1↓, 2,   PGM1↓, 1,   PIP3↑, 1,   PKM2↓, 19,   PKM2∅, 1,   Pyruv↓, 1,   R5P↝, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   p‑S6↓, 1,   SCD1↓, 2,   SIRT1↓, 5,   SIRT1↑, 4,   SIRT2↑, 1,   SREBP1/SREBF1↓, 3,   SREBP2↓, 2,   TCA↓, 1,   Warburg↓, 8,  

Cell Death(tgid=5) ⓘ

AIF↑, 4,   APAF1↑, 6,   Apoptosis?, 3,   Apoptosis↓, 7,   Apoptosis↑, 234,   mt-Apoptosis↑, 1,   ASC↓, 1,   ASC↑, 1,   ASK1↑, 1,   BAD↓, 1,   BAD↑, 3,   Bak↑, 2,   BAX↓, 1,   BAX↑, 84,   Bax:Bcl2↑, 14,   Bcl-2↓, 99,   Bcl-xL↓, 15,   BIM↑, 2,   BNIP3↑, 1,   Casp↑, 24,   Casp1↓, 1,   Casp1↑, 1,   cl‑Casp1↑, 1,   proCasp1↓, 1,   Casp10↓, 1,   Casp10∅, 1,   Casp12↑, 1,   cl‑Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 2,   Casp3↑, 94,   cl‑Casp3↑, 24,   Casp7↑, 13,   cl‑Casp7↑, 1,   Casp8↓, 1,   Casp8↑, 23,   Casp8∅, 1,   cl‑Casp8↑, 3,   proCasp8↑, 1,   Casp9↓, 1,   Casp9↑, 58,   p‑Casp9↑, 1,   cl‑Casp9↑, 8,   cFLIP↓, 2,   Cupro↑, 1,   Cyt‑c↓, 2,   Cyt‑c↑, 47,   Cyt‑c↝, 1,   DR5↑, 11,   DR5∅, 1,   Endon↑, 1,   FADD↑, 3,   FADD∅, 1,   Fas↓, 2,   Fas↑, 11,   FasL↓, 1,   FasL↑, 4,   Ferroptosis↑, 22,   GSDMD↑, 2,   IAP1↓, 5,   IAP2/BIRC3↓, 2,   cl‑IAP2/BIRC3↑, 1,   iNOS↓, 7,   Mcl-1↓, 10,   Mcl-1↑, 1,   MDM2↓, 7,   MDM2↑, 1,   MOMP↓, 1,   MOMP↑, 3,   Necroptosis↑, 2,   necrosis↑, 2,   NOXA↑, 2,   P2X7↓, 1,   p38↓, 6,   p38↑, 9,   p‑p38↓, 4,   p‑p38↑, 3,   p‑p38↝, 1,   Paraptosis↑, 1,   PDCD4↑, 1,   PUMA↑, 2,   Pyro↑, 3,   RIP1↓, 1,   survivin↓, 38,   TNFR 1↓, 1,   TNFR 1↑, 1,   TRAIL↑, 1,   TRAILR↑, 1,   TumCD↓, 2,   TumCD↑, 9,   TUNEL↑, 1,   XIAP↓, 19,   YAP/TEAD↓, 6,   YAP/TEAD↑, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ABL1↓, 1,   Akt↓, 122,   Akt↑, 5,   Akt↝, 1,   p‑Akt↓, 44,   p‑Akt↑, 1,   AKT1↓, 4,   AKT3↓, 1,   p‑CaMKII ↓, 1,   CIP2A↓, 1,   CK2↓, 4,   cMET↓, 1,   p‑cMET↑, 2,   cSrc↓, 1,   EF-1α↓, 1,   EGFR↓, 34,   p‑EGFR↓, 1,   ERK↓, 31,   ERK↑, 7,   ERK↝, 2,   p‑ERK↓, 18,   p‑ERK↑, 1,   p‑ERK↝, 1,   FGFR1↓, 1,   HER2/EBBR2↓, 10,   p‑HER2/EBBR2↓, 1,   IGF-1R↓, 2,   IGFR↓, 1,   p‑IGFR↓, 1,   IKKα↓, 10,   IKKα↝, 1,   p‑IKKα↓, 1,   IR↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   p‑IκB↑, 1,   JAK↓, 6,   JAK↝, 1,   p‑JAK↓, 1,   JAK1↓, 2,   JAK2↓, 11,   p‑JAK2↓, 2,   p‑JAK3↓, 1,   JNK↓, 3,   JNK↑, 10,   JNK↝, 1,   p‑JNK↓, 2,   p‑JNK↑, 1,   p‑JNK↝, 1,   p‑MAP2K1/MEK1↓, 1,   MAPK↓, 27,   MAPK↑, 9,   MAPK↝, 1,   p‑MAPK↓, 2,   p‑MAPK↑, 1,   MEK↓, 4,   p‑MEK↓, 2,   mTOR↓, 67,   mTOR↑, 4,   mTOR↝, 1,   p‑mTOR↓, 12,   mTORC2↓, 2,   mTORC2↑, 1,   NRAS↓, 1,   p42↑, 1,   P70S6K↓, 5,   p‑P70S6K↓, 1,   P90RSK↓, 1,   p‑P90RSK↑, 1,   p‑PDGFR-BB↓, 1,   PDGFRA↓, 1,   PFKFB2↓, 1,   PI3K↓, 83,   PI3K↝, 1,   p‑PI3K↓, 13,   PI3K/Akt↓, 4,   PI3k/Akt/mTOR↓, 1,   PIK3CA↓, 1,   PKA↓, 1,   PKCδ↓, 8,   p‑PKCδ↓, 1,   PP2A↑, 1,   PRAS40↑, 1,   PTEN↑, 22,   PTK2B / PYK2↓, 1,   Raf↓, 3,   c-Raf↓, 1,   RAS↓, 10,   RAS↑, 1,   p‑S6K↓, 1,   SGK1↓, 1,   Sp1/3/4↓, 19,   Src↓, 4,   p‑Src↓, 1,   STAT↓, 6,   p‑STAT↓, 1,   p‑STAT2↓, 1,   STAT3↓, 57,   STAT3↑, 3,   p‑STAT3↓, 10,   p‑STAT3↑, 2,   STAT5↓, 1,   STAT6↓, 3,   THEM4/CTMP↑, 1,   TSC2↑, 2,   p‑TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 2,   ATF4↑, 6,   ATF4↝, 1,   CBP↓, 2,   cJun↓, 6,   cJun↑, 2,   p‑cJun↓, 1,   cMyc↓, 26,   DNMT1↓, 4,   DNMT1↑, 1,   DNMTs↓, 2,   EZH2↓, 1,   FOXM1↓, 2,   FOXO↑, 2,   FOXO1↓, 2,   FOXO1↑, 1,   FOXO3↑, 4,   p‑FOXO3↓, 1,   FOXO4↓, 1,   FOXO4↑, 1,   H3↑, 1,   ac‑H3↑, 2,   H4↑, 2,   ac‑H4↑, 1,   HATs↓, 5,   HATs↑, 1,   HDAC↓, 11,   HDAC1↓, 4,   HDAC3↓, 1,   HDAC4↓, 1,   HDAC6↓, 2,   HDAC8↓, 1,   HES1↓, 2,   HMTs↓, 1,   HOXB-AS1↓, 1,   JPT1/HN1↓, 1,   KISS1↑, 1,   LINC01116↓, 1,   Matr↓, 1,   METTL7A↑, 1,   miR-107↑, 2,   miR-10b-5p↓, 1,   miR-124-3p↓, 1,   miR-130a↓, 2,   miR-133a-3p↑, 1,   miR-139-5p↑, 3,   miR-145↑, 1,   miR-149↑, 1,   miR-155↓, 2,   miR-182-5p↓, 1,   miR-192-5p↑, 1,   miR-194↑, 1,   miR-200b↑, 1,   miR-205↑, 2,   miR-206↑, 1,   miR-21↓, 8,   miR-223-3p↓, 1,   miR-224↓, 2,   miR-25-5p↓, 1,   miR-29b↑, 1,   miR-301a-3p↓, 1,   miR-30a-5p↑, 1,   miR-340↓, 2,   miR-34a↓, 1,   miR-34a↑, 5,   miR-375↑, 2,   miR-384↑, 1,   miR-422a↑, 2,   miR-542↓, 1,   miR-590-3p↑, 1,   miR-592↑, 1,   miR-7641↓, 1,   miR-99↑, 1,   Myc↓, 1,   Myc↑, 1,   NDRG1↑, 1,   OCT4↓, 12,   other?, 1,   other↓, 2,   other↑, 3,   other↝, 11,   PCAF↓, 1,   PhotoS↑, 2,   RASSF1A↑, 1,   sonoS↑, 1,   SOX2↓, 10,   SOX4↓, 1,   SOX4↑, 1,   SUV39H↓, 1,   TCF-4↓, 1,   TLE1↓, 1,   tumCV↓, 71,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 18,   cl‑CHOP/DDIT3↑, 1,   CUL1↝, 1,   CUL5↝, 1,   eIF2α↓, 1,   eIF2α↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 27,   Erlin1↑, 1,   GRP78/BiP?, 1,   GRP78/BiP↓, 2,   GRP78/BiP↑, 8,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↑, 1,   e-HSP70/HSPA5↓, 1,   HSP90↓, 13,   HSPs↓, 1,   IRE1↑, 3,   OTUB2↓, 1,   PDI↑, 1,   PERK↑, 9,   p‑PERK↑, 1,   Proteasome↓, 1,   UPR↓, 1,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   ATG3↑, 1,   ATG5↓, 1,   ATG5↑, 2,   ATG7↑, 2,   Beclin-1/ATG6↓, 4,   Beclin-1/ATG6↑, 5,   LC3‑Ⅱ/LC3‑Ⅰ↑, 3,   LC3A↑, 2,   LC3B↑, 1,   LC3B-II↓, 1,   LC3B-II↑, 1,   LC3I↑, 1,   LC3II↓, 1,   LC3II↑, 7,   LC3s↑, 1,   MitoP↑, 1,   p62↓, 4,   p62↑, 3,   p‑p62↑, 1,   PARK2↑, 3,   RUBCN↓, 1,   SESN2↑, 1,   TumAuto↓, 1,   TumAuto↑, 42,   TumAuto⇅, 1,   TumAuto↝, 1,   ULK1/ATG1↑, 1,   VMP-1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 3,   BRCA1↓, 2,   BRCA1↑, 2,   BRCA2↑, 1,   DNAdam↓, 1,   DNAdam↑, 33,   DNArepair↓, 5,   ERCC1↓, 2,   ERCC3↑, 1,   ERCC4/XPF↓, 1,   m-FAM72A↓, 1,   hTERT/TERT↓, 3,   Ku70/XRCC6↓, 1,   p16↑, 2,   P53?, 1,   P53↓, 1,   P53↑, 50,   p‑P53↑, 3,   p73↑, 1,   PARP↓, 3,   PARP↑, 9,   cl‑PARP↑, 42,   PARP1↑, 1,   cl‑PARP1↑, 1,   PCNA↓, 22,   PCNA↑, 1,   POLD1↓, 1,   Telomerase↓, 5,   TOP1↓, 3,   TOP2↓, 2,   TOP2↑, 1,   TP53↑, 2,   XRCC1↓, 1,   γH2AX↑, 5,   γH2AX↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 2,   CDK1↓, 9,   CDK1↑, 1,   CDK2↓, 20,   CDK2↑, 3,   CDK4↓, 25,   CDK4↑, 2,   CDK4∅, 1,   CDK4/6↓, 1,   CDK6↓, 10,   CDK6↑, 2,   CDK6∅, 1,   CDK7↓, 1,   cellSen↑, 1,   CHK1↓, 1,   CHK1↑, 1,   p‑CHK1↑, 1,   Chk2↑, 1,   p‑Chk2↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 7,   CycB/CCNB1↓, 15,   cycD1/CCND1↓, 53,   cycD1/CCND1↑, 2,   cycD1/CCND1∅, 1,   CycD3↓, 3,   cycE/CCNE↓, 14,   E2Fs↓, 2,   Ki-67↓, 31,   MAD↓, 1,   P21?, 1,   P21↓, 3,   P21↑, 40,   p27/CDKN1B↓, 2,   p27/CDKN1B↑, 10,   p‑pRB↓, 2,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 3,   RRM2↓, 1,   Securin↓, 1,   TumCCA↓, 6,   TumCCA↑, 149,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 2,   p‑4E-BP1↓, 2,   ALDH↓, 8,   ALDH1A1↓, 1,   Axin2↑, 1,   BMI1↓, 1,   BMP2↓, 1,   BMPs↑, 2,   CD133↓, 11,   CD133↑, 1,   CD24↓, 4,   CD34↓, 1,   cFos↓, 7,   p‑cFos↓, 1,   cMYB↓, 1,   CSCs↓, 38,   Diff↑, 5,   FGF↓, 2,   FGF↑, 1,   Gli↓, 1,   Gli1↓, 13,   HH?, 1,   HH↓, 12,   IGF-1↓, 4,   IGFBP3↓, 1,   IGFBP3↑, 2,   JAG1↓, 1,   Jun↓, 2,   Ki-67↓, 31,   Let-7↑, 1,   LRP6↓, 2,   p‑LRP6↓, 2,   MCM2↓, 1,   mTORC1↓, 5,   Nanog↓, 10,   Nestin↓, 3,   NOTCH↓, 10,   NOTCH↑, 1,   NOTCH1↓, 5,   NOTCH1↝, 1,   NOTCH3↓, 3,   OGFr↑, 2,   p300↓, 3,   PCLAF↓, 1,   Piezo1↑, 2,   PTCH1↓, 3,   PTCH2↓, 1,   SCF↓, 1,   Shh↓, 4,   Smo↓, 6,   STAT1↓, 1,   p‑STAT1↓, 1,   Sufu↓, 1,   TAZ↓, 1,   TOPflash↓, 2,   TumCG?, 2,   TumCG↓, 108,   TumCG↑, 3,   TumCG∅, 1,   TumCP?, 1,   TumCP↓, 242,   TumCP↑, 5,   tyrosinase↓, 1,   URGCP/URG4↓, 1,   WDR72↓, 1,   Wnt↓, 30,   Wnt/(β-catenin)↓, 7,   ZFX↓, 1,  

Migration(tgid=13) ⓘ

AGRN↓, 1,   annexin II↓, 1,   AntiAg?, 1,   AntiAg↑, 3,   AP-1↓, 10,   AP-1↝, 1,   ASAP2↓, 1,   Ca+2↑, 20,   CAFs/TAFs↓, 1,   CAFs/TAFs↝, 1,   cal2↑, 2,   Cav1↓, 1,   Cofilin↓, 1,   p‑Cofilin↑, 2,   COL11A1↓, 1,   E-cadherin↓, 6,   E-cadherin↑, 70,   EMT?, 1,   EMT↓, 124,   EMT↑, 4,   EpCAM↓, 3,   F-actin↓, 3,   FAK↓, 14,   FAK↑, 1,   p‑FAK↓, 3,   Fibronectin↓, 7,   GLI2↓, 2,   ITGA2↓, 1,   ITGA5↓, 1,   ITGA6↓, 1,   ITGB1↓, 4,   ITGB3↓, 1,   ITGB4↓, 3,   ITGB6↓, 1,   LAMs↓, 1,   LEF1↓, 2,   LIMK2↓, 1,   LRP1↓, 1,   MALAT1↓, 3,   MET↓, 2,   MET↑, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP1↓, 5,   MMP13↓, 5,   MMP14↓, 2,   MMP16↓, 2,   MMP17↓, 1,   MMP2?, 1,   MMP2↓, 117,   MMP2↝, 1,   MMP3↓, 8,   MMP7↓, 11,   MMP9?, 1,   MMP9↓, 134,   MMP9↑, 1,   MMP9↝, 1,   MMPs↓, 32,   MTA1↓, 2,   MUC1↓, 1,   MUC4↓, 1,   N-cadherin?, 1,   N-cadherin↓, 53,   NEDD9↓, 3,   p44↑, 1,   PAK1↓, 1,   pax↓, 1,   PDGF↓, 4,   RECK↑, 2,   RHBDD1↓, 1,   Rho↓, 5,   ROCK1↓, 8,   Sharpin↓, 1,   Slug↓, 27,   Smad1↓, 2,   Smad1↑, 1,   Smad1↝, 1,   SMAD2↓, 4,   p‑SMAD2↓, 9,   SMAD3↓, 8,   p‑SMAD3↓, 7,   SMAD4↓, 1,   p‑SMAD4↓, 1,   Snail↓, 44,   Snail↑, 1,   T-cadherin↑, 1,   talin?, 1,   talin↓, 1,   TET1↓, 1,   TET1↑, 3,   TGF-β↓, 18,   TGF-β↑, 3,   TGF-β↝, 1,   TGF-β1↓, 3,   THBS1↓, 1,   TIMP1↓, 1,   TIMP1↑, 7,   TIMP2↓, 2,   TIMP2↑, 9,   TIMP3↑, 2,   TRIB3↑, 1,   TSC1↑, 1,   TSP-1↑, 1,   TumCA↓, 10,   TumCA↑, 1,   TumCI?, 1,   TumCI↓, 543,   TumCI↑, 7,   TumCMig?, 1,   TumCMig↓, 346,   TumCMig↑, 5,   TumMeta↓, 119,   TumMeta↑, 5,   Twist↓, 16,   Twist↑, 1,   TXNIP↑, 1,   uPA↓, 14,   uPAR↓, 2,   UroPA↓, 1,   Vim?, 1,   Vim↓, 58,   Vim↑, 1,   vinculin↓, 1,   Zeb1↓, 17,   Zeb1↑, 1,   ZEB2↓, 3,   ZEB2↑, 1,   α-SMA↓, 3,   α-SMA↑, 1,   α-tubulin↑, 2,   β-catenin/ZEB1↓, 53,   β-catenin/ZEB1↑, 2,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 96,   angioG↑, 2,   EGR1↓, 1,   EGR4↓, 1,   eNOS↓, 1,   HIF-1↓, 6,   Hif1a↓, 53,   Hif1a↑, 1,   Hif1a↝, 1,   NO↓, 1,   PHDs↑, 1,   TXA2↓, 1,   VEGF↓, 69,   VEGF↑, 1,   VEGFR1↓, 2,   VEGFR2/KDR/Flk1↓, 8,  

Barriers & Transport(tgid=15) ⓘ

AQPs↓, 1,   BBB↑, 2,   CLDN1↓, 1,   CLDN1↑, 1,   CX43/GJA1↓, 1,   EPR↑, 2,   GLUT1↓, 12,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,   MMP↓, 65,   MMP↑, 1,   MPT↑, 4,   OATPs↓, 1,   TRPM7↓, 2,   TRPM7↑, 1,   TRPV1↑, 1,   ZO-1↓, 1,   ZO-1↑, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 1,   CD25+↑, 1,   CD4+↓, 1,   CD4+↑, 2,   CD44↓, 13,   CD47↓, 1,   CD8+↑, 5,   p‑cDC2↓, 1,   COX1↓, 3,   COX2/PTGS2↓, 37,   COX2/PTGS2↑, 2,   COX2/PTGS2↝, 1,   CXCL12↓, 2,   CXCR2↓, 1,   CXCR4↓, 11,   DR4↑, 7,   DR4∅, 1,   FOXP3↑, 1,   Gal-3↓, 2,   HLA-I/II↑, 1,   HMGB1↓, 2,   ICAM-1↓, 4,   IFN-γ↑, 1,   Igs↑, 1,   IL1↓, 3,   IL10↓, 1,   IL12↓, 1,   IL12↑, 1,   IL18↓, 2,   IL1α↓, 2,   IL1β↓, 11,   IL2↓, 2,   IL6↓, 26,   IL6↑, 1,   IL8↓, 8,   Imm↑, 11,   Imm↝, 2,   Inflam↓, 34,   Inflam↝, 2,   IRAK4↓, 1,   LIF↑, 1,   LRIG1↑, 1,   M2 MC↓, 1,   MCP1/CCL2↓, 5,   MCT1↓, 1,   MIP2↓, 1,   NF-kB↓, 115,   NF-kB↑, 6,   NF-kB↝, 2,   p‑NF-kB↓, 4,   p‑NF-kB↑, 1,   NFKBIZ/IκBζ↓, 1,   NK cell↑, 3,   NLRP3↓, 5,   NLRP3↑, 2,   p65↓, 5,   p‑p65↓, 2,   PD-1↓, 3,   PD-L1↓, 8,   PD-L1↑, 2,   PGE2↓, 12,   PSA↓, 2,   T-Cell↑, 1,   TCF↓, 2,   Th1 response↑, 1,   TLR2↓, 1,   TLR4↓, 8,   TNF-α↓, 20,   TNF-α↑, 3,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   WFDC10A↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↓, 1,   pH↑, 1,   e-pH↑, 3,   i-pH↓, 1,   TAMS↓, 1,   TAMS↝, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   PTN↓, 1,  

Protein Aggregation(tgid=19) ⓘ

BACE/β-secretase↓, 1,   XO↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AhR↑, 2,   AhR↓, 1,   AR↓, 10,   ER-α36↓, 2,   ERα/ESR1↓, 1,   Estro↝, 1,   EstroRS/ERS↑, 1,   FGF21↓, 1,   NR3C2/MR↑, 2,   PPARα↓, 1,   PPARα↑, 1,   PPARα↝, 1,   PPARγ↑, 5,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 3,   AKR1B10↓, 1,   BioAv↓, 22,   BioAv↑, 23,   BioAv↝, 11,   BioEnh?, 1,   BioEnh↑, 2,   ChemoSen↓, 2,   ChemoSen↑, 107,   CompStab↓, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   CYP2E1↑, 1,   CYP3A4↓, 2,   DDS↑, 1,   Dose↓, 5,   Dose↑, 3,   Dose↝, 42,   Dose∅, 4,   eff↓, 20,   eff↑, 55,   eff↝, 3,   eff∅, 1,   GSTZ1↓, 1,   Half-Life↓, 7,   Half-Life↑, 2,   Half-Life↝, 7,   MDR1↓, 2,   MRP1/ABCC1↓, 2,   NAT↓, 1,   P-gp/ABCB1↓, 14,   P450↓, 1,   RadioS?, 1,   RadioS↑, 31,   selectivity↑, 62,   Synergy↑, 75,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   AFP↓, 1,   ALAT↓, 2,   ALB↑, 1,   ALP↓, 2,   AR↓, 10,   ascitic↓, 1,   AST?, 1,   AST↓, 1,   BMD↑, 2,   BP↓, 1,   BRCA1↓, 2,   BRCA1↑, 2,   CRP↓, 1,   DBIL↓, 1,   EGFR↓, 34,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   EstroRS/ERS↑, 1,   EZH2↓, 1,   Ferritin↓, 1,   FOXM1↓, 2,   HER2/EBBR2↓, 10,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 3,   IBIL↓, 1,   IL6↓, 26,   IL6↑, 1,   LDH↓, 7,   LDH↑, 2,   Myc↓, 1,   Myc↑, 1,   NOS2↓, 1,   PD-L1↓, 8,   PD-L1↑, 2,   PSA↓, 2,   TBIL↓, 1,   TG/TAG↓, 1,   TP53↑, 2,   TRIB3↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 32,   AntiCan⇅, 1,   AntiCan∅, 1,   antiD↑, 1,   AntiDiabetic↑, 2,   antiNeop↑, 3,   AntiTum↓, 3,   AntiTum↑, 23,   cachexia↓, 1,   cardioP↑, 6,   CardioT↑, 1,   chemoP?, 1,   chemoP↑, 18,   chemoPv↑, 15,   ChemoSideEff↓, 3,   fatigue↓, 2,   FTO↓, 1,   FTO↑, 1,   hepatoP↓, 1,   hepatoP↑, 4,   Mucositis↓, 1,   neuroP↑, 4,   NP/CIPN↓, 1,   OS↑, 11,   Pain↓, 1,   PFS↑, 1,   Pin1↓, 1,   QoL↑, 5,   radioP↑, 6,   Remission↑, 1,   RenoP↑, 2,   Risk↓, 8,   Risk↑, 1,   Sleep↑, 1,   Strength↑, 1,   Symptoms↓, 1,   toxicity?, 1,   toxicity↓, 19,   toxicity↑, 4,   toxicity↝, 5,   toxicity∅, 1,   TumVol↓, 25,   TumVol∅, 1,   TumW↓, 14,   TumW∅, 1,   Weight∅, 1,   Wound Healing↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1,   GutMicro↑, 3,   Sepsis↓, 2,  
Total Targets: 1052

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 4,   antiOx↑, 51,   Catalase↑, 18,   Fenton↓, 1,   GPx↑, 13,   GPx1↑, 1,   GSH↑, 13,   GSR↑, 1,   GSTs↑, 2,   H2O2↓, 1,   HDL↑, 2,   HO-1?, 1,   HO-1↓, 1,   HO-1↑, 11,   hyperG↝, 1,   Iron∅, 1,   Keap1↓, 2,   lipid-P↓, 17,   MDA↓, 12,   MPO↓, 2,   NOX↓, 1,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 23,   RNS↓, 4,   ROS↓, 44,   ROS↑, 1,   SOD↑, 16,   SOD1↑, 3,   SOD2↑, 1,   TAC↑, 3,   TBARS↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compII↑, 1,   compIII↑, 1,   HSP60/HSPD1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 6,   AMPK↓, 1,   AMPK↑, 2,   ATP↓, 1,   ATP↑, 1,   cytoP450↓, 1,   glucose↓, 2,   glucose↑, 1,   glucose↝, 2,   GlucoseCon↑, 2,   HMG-CoA↓, 2,   LDL↓, 3,   NAD↓, 1,   NADPH↓, 2,   NADPH↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   BAX↓, 3,   Bcl-2↓, 1,   Bcl-2↑, 1,   Bcl-xL↑, 1,   Casp12↓, 1,   Casp3↓, 5,   cl‑Casp3↓, 1,   cl‑Casp8↓, 1,   Casp9↓, 3,   Cyt‑c↓, 1,   Fas↓, 1,   GranB/GZMB↓, 1,   iNOS↓, 9,   iNOS↑, 1,   p38↓, 1,   RIP1↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 4,   p‑Akt↑, 1,   ERK↓, 1,   p‑ERK↑, 1,   HGF/c-Met↑, 1,   IKKα↑, 1,   JAK2↑, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 5,   MAPK↑, 2,   mTOR↓, 2,   mTOR↑, 2,   PI3K↑, 4,   PKCδ↓, 1,   PKCδ↑, 1,   STAT3↑, 2,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,   ATF4↓, 2,   cMyc↓, 1,   HDAC↓, 1,   HOTAIR↑, 1,   other↓, 2,   other↑, 1,   other↝, 5,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 3,   CHOP/DDIT3↑, 1,   p‑eIF2α↓, 1,   ER Stress↓, 2,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   GADD34↓, 1,   P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↝, 1,   neuroG↑, 1,   TumCP↓, 3,  

Migration(tgid=13) ⓘ

AntiAg↑, 2,   Ca+2↝, 1,   EMT↑, 1,   MMP9↓, 1,   PAI-1/SERPINE1↓, 1,   p‑Rac1↓, 1,   TGF-β↓, 1,   TGF-β↑, 1,   TumCI↓, 2,   TumCI∅, 1,   TumCMig↓, 1,   TumCMig∅, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   E-sel↓, 1,   Hif1a↓, 1,   NO↓, 5,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   GastroP↑, 2,   GLUT2↑, 2,   GLUT3↑, 1,   GLUT4↑, 1,   IBI↑, 3,   MMP↑, 2,   MUC5AC↓, 1,   VGSC↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCL11↓, 1,   CD25+↑, 1,   CD4+↑, 2,   COX2/PTGS2↓, 12,   FOXP3↑, 1,   HMGB1↓, 1,   IFN-γ↓, 2,   IL1↓, 2,   IL10↓, 3,   IL10↑, 3,   IL12↓, 2,   IL17↓, 1,   IL1β↓, 8,   IL4↓, 1,   IL4↑, 1,   IL6↓, 15,   Imm↓, 1,   Imm↑, 4,   Inflam?, 1,   Inflam↓, 57,   Inflam↑, 2,   IRF3↓, 1,   LPS↓, 1,   M2 MC↑, 1,   MCP1/CCL2↓, 1,   MyD88↓, 1,   NF-kB↓, 13,   NLRP3↓, 3,   PGE2↓, 5,   TLR2↓, 2,   TLR4↓, 4,   TNF-α↓, 15,   Treg lymp↝, 1,   TRIF↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   Ach↑, 1,   AChE↓, 5,   AChE↑, 1,   BChE↓, 1,   BDNF↓, 1,   BDNF↑, 2,   proBDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,   NGF↑, 2,   TPH1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 2,   APP↓, 1,   Aβ↓, 4,   BACE/β-secretase↓, 1,   tau↓, 1,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↓, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 13,   BioAv↑, 20,   BioAv⇅, 1,   BioAv↝, 9,   BioEnh↑, 1,   CompStab↑, 1,   CompStab↝, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 7,   eff↑, 5,   Half-Life↓, 3,   Half-Life↝, 2,   Half-Life∅, 1,   P-gp/ABCB1↓, 1,   Synergy↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 6,   ALP↓, 2,   AST↓, 6,   BMD↑, 2,   BP↓, 1,   BUN↓, 1,   creat↓, 1,   CRP↓, 3,   IL6↓, 15,   LDH↓, 2,   SpO2↑, 1,   TG/TAG↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 1,   AntiAge↑, 2,   antiAll↑, 7,   AntiArt↑, 3,   AntiCan↑, 7,   antiCG↑, 1,   antiD↓, 1,   antiD↑, 1,   AntiDiabetic↑, 9,   antiPs↑, 1,   AntiTum↓, 1,   AntiTum↑, 3,   ANXi↓, 1,   cardioP↑, 19,   chemoP↑, 1,   chemoPv↑, 2,   cognitive↑, 6,   diuretic↑, 1,   hepatoP↑, 17,   memory↑, 3,   Mood↑, 1,   neuroP?, 1,   neuroP↑, 34,   Obesity↓, 3,   OS↑, 1,   Pain↓, 2,   radioP↑, 3,   RenoP↑, 6,   Risk↓, 1,   Sleep↑, 1,   Stroke↓, 4,   toxicity↓, 23,   toxicity↑, 2,   toxicity↝, 6,   toxicity∅, 7,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 5,   AntiFungal↑, 1,   AntiP↑, 2,   AntiViral↑, 6,   Bacteria↓, 11,   GutMicro↑, 10,   Sepsis↓, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 271

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
21 Curcumin
15 Resveratrol
14 Quercetin
13 Matrine
12 Honokiol
12 Magnolol
12 Shikonin
11 Berberine
11 Fisetin
10 Apigenin (mainly Parsley)
10 EGCG (Epigallocatechin Gallate)
10 Sulforaphane (mainly Broccoli)
9 Thymoquinone
8 Melatonin
8 Eugenol
8 Garcinol
8 Luteolin
7 Ashwagandha(Withaferin A)
7 Betulinic acid
7 Chlorogenic acid
7 Chrysin
7 Licochalcone A
7 Magnetic Fields
6 Metformin
6 Cinnamon
6 Dandelion Root
6 Emodin
6 Formononetin
6 Ginkgetin
6 Piperlongumine
5 Astragalus
5 Gemcitabine (Gemzar)
5 Ferulic acid
5 Hyperoside
5 Lycopene
5 Morin
5 Pterostilbene
4 Artemisinin
4 Baicalein
4 Carvacrol
4 Celastrol
4 Cyclopamine
4 Radiotherapy/Radiation
4 Gambogic Acid
4 Isoliquiritigenin
4 Juglone
4 Nimbolide
4 Phenethyl isothiocyanate
4 Rosmarinic acid
4 Silymarin (Milk Thistle) silibinin
4 Urolithin
3 Silver-NanoParticles
3 Alpha-Lipoic-Acid
3 Berbamine
3 Brucea javanica
3 brusatol
3 Capsaicin
3 NTP, Non-Thermal Plasma,Cold Atmospheric Plasma
3 Centella asiatica / Gotu kola → asiaticoside
3 chaetocin
3 Zinc
3 Propolis -bee glue
3 Crocetin
3 Copper and Cu NanoParticles
3 Diindolylmethane
3 Evodiamine
3 Gallic acid
3 Paclitaxel/Taxol
3 Genistein (soy isoflavone)
3 Hydrogen Gas
3 Indole-3-carbinol
3 iodine
3 Magnetic Field Rotating
3 Mushroom Lion’s Mane, Hericium erinaceus
3 Bicarbonate(Sodium)
3 Piperine
3 Whole Body Vibration
2 alpha Linolenic acid
2 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
2 Aspirin
2 Astaxanthin
2 Beta-Caryophyllene
2 Boron
2 Boswellia (frankincense)
2 α-Bisabolol / Chamomile oil
2 Caffeic Acid Phenethyl Ester (CAPE)
2 Celecoxib
2 Hydroxycinnamic-acid
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Dasatinib/Phyrago
2 Deguelin
2 Disulfiram
2 Ellagic acid
2 Ginkgolic acids
2 Ginkgolide B
2 5-fluorouracil
2 Graviola
2 Grapeseed extract
2 Hibiscus sabdariffa
2 HydroxyTyrosol
2 isoflavones
2 isoorientin
2 isoquercitrin
2 itraconazole
2 Kaempferol
2 low dose naltrexone
2 Licorice
2 Linalool
2 Lutein
2 Modified Citrus Pectin
2 Mushroom Chaga, Inonotus obliquus
2 Marjoram (Origanum majorana)
2 Cisplatin
2 salinomycin
2 Sulfasalazine
2 Selenite (Sodium)
2 Aflavin-3,3′-digallate
2 Vitamin C (Ascorbic Acid)
1 1,8-Cineole
1 3-bromopyruvate
1 Ajoene (compound of Garlic)
1 DTS(dibenzyl trisulphide) from Anamu
1 Andrographis
1 Ascorbyl Palmitate
1 Aloe anthraquinones
1 Biochanin A
1 Atorvastatin
1 bempedoic acid
1 Bufalin/Huachansu
1 Bacopa monnieri
1 Butyrate
1 Carnosic acid
1 chitosan
1 Selenium NanoParticles
1 Chlorophyllin
1 Carvone
1 CUSP9
1 Cynaropicrin
1 Cysteamine
1 Dichloroacetate
1 Date Fruit Extract
1 Mistletoe/Viscum album Extracts
1 Ginkgo biloba-EGb 761
1 eicosapentaenoic acid
1 Sorafenib (brand name Nexavar)
1 Fucoidan
1 Galloflavin
1 Ginkgo biloba
1 Geraniol
1 Ginseng
1 γ-linolenic acid (Borage Oil)
1 Gossypol/AT-101
1 Proanthocyanidins
1 Hops (Humulus lupulus)
1 Isobavachalcone
1 phytic acid, Inositol hexakisphosphate
1 Ivermectin
1 Isovitexin
1 Lactoferrin/Talactoferrin
1 SDG/lignans
1 mebendazole
1 Methyl Jasmonate
1 methylseleninic acid
1 Methyl salicylate / Sweet Birch oil
1 doxorubicin
1 immunotherapy
1 Magnesium
1 Methylsulfonylmethane
1 Noscapine
1 Oroxylin A
1 Oleuropein
1 Orlistat
1 Psoralidin
1 Docetaxel
1 Germacranolide sesquiterpene lactone
1 Rauwolfia serpentina/Indian Snakeroot
1 Salvia miltiorrhiza
1 Terpinen-4-ol / Tea Tree Oil
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Usnic acid
1 Arsenic trioxide
1 Vitamin K2
1 VitK3,menadione
1 Vitexin
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:324  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page